anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: ketamine group will be infused after intubation and terminated at the start of skin closure

Ketamine: Infusion at a rate of 10 mcg/kg/min
Eligibility criteria:
Inclusion Criteria:

Adult (>/=18)
male or female
Undergoing surgery for multilevel (>2 level) spinal fusion from a posterior approach.
General anesthesia
English speakers such that they can complete the pain score and satisfaction questionnaires whose scores are a critical outcome variable.
If female, subject is non-lactating and is either: a. Post-menopausal or post hysterectomy; b. Of childbearing potential but is not pregnant at time of baseline as determined by pre-surgical pregnancy testing.
Subject is American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.

Exclusion Criteria:

Cognitively impaired (by history)
Subject with a history of psychosis
Subject known to have significant hepatic disease
Subject for whom opioids or ketamine are contraindicated
Patients with narrow angle glaucoma
Increased intracranial or intraocular pressure
If female, is either pregnant or lactating.
Intervention: Propranolol
Trial phase: Not Applicable
ATC code: C07AA05 | C07BA05 | C07FX01
SMILES: CC(C)NCC(O)COc1cccc2ccccc12
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 5
Group description: Allocated to propranolol (n=5)

Lost to follow-up (n=2)

Withdrew after baseline visit due to not feeling seeing a benefit (n=1)
Withdrew after 6-week visit -no reason given (n=1)

Completed (n=4 at 6 weeks) (n=3 at 12 weeks)
Eligibility criteria:
Inclusion Criteria:

Diagnosis of autism spectrum disorder (ASD), defined in this study by the DSM-V criteria plus Autism Diagnostic Observation Schedule (ADOS) criteria for Autism.
Aged 3-8
Participants must also be enrolled in an early behavioral intervention program at the Thompson Center or another institution in Missouri for the duration of the study.

Exclusion Criteria:

Non-autism learning disability (e.g. dyslexia)
Major psychiatric diagnosis (e.g. major depression, schizophrenia, bipolar disorder)
Other neurological diagnosis
Major head trauma
Any of the following exclusionary criteria related to propranolol (diabetes, reactive airway/pulmonary disease, thyroid disease, bradyarrhythmias, unexplained syncope, narrow angle glaucoma, known hypersensitivity/adverse reaction to beta-blockers, potentially interacting drugs, underweight < 15 kg)
Any of the following exclusionary criteria related to the use of electrocardiogram (history of rash from adhesives)
Any of the following exclusionary criteria related to the pupillary reflex measurement (uncorrectable visual acuity impairment).
Participants with a heart rate of less than 60 or a systolic blood pressure of less than 75 at the outset of the study will be excluded.
Intervention: Desipramine
Trial phase: Phase 2
ATC code: N06AA01
SMILES: CNCCCN1c2ccccc2CCc2ccccc21
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 17
Group description: Desipramine 200 mg administered 2 hours before normal sleep time on the first study night or second study night.
Eligibility criteria:
Inclusion Criteria:

Healthy control subjects

Exclusion Criteria:

Cardiovascular disease other than well controlled hypertension
Depression
Intervention: Everolimus
Trial phase: Phase 4
ATC code: L01EG02 | L04AA18
SMILES: COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Subjects on mTOR inhibitor (everolimus) for 6 months, added to standard of care immunosuppressive regimen
Eligibility criteria:
Inclusion Criteria:

Solid organ (kidney, kidney/pancreas, or liver) transplant recipient
Male or female ≥ 18 years of age.
Documentation of HIV-1 infection diagnosis as evidenced by any licensed ELISA and confirmation by Western Blot, or documented history of detectable HIV-1 RNA)
HIV-1 plasma RNA <50 copies/ml for at least 2 years with at least one measurement per year and most recent viral load within 16 weeks of enrollment and study drug initiation. Episodes of a single HIV plasma RNA 50 - 500 copies/ml will not exclude participation if the subsequent HIV plasma RNA was <50 copies/ml.
CD4+ T cell counts greater than 200 cell/µl within 16 weeks of enrollment and study drug initiation.
Receiving combination antiretroviral therapy (at least 3 agents)
Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Patients who are intending to modify antiretroviral therapy in the next 6 months for any reason.
Serious illness requiring hospitalization or parenteral antibiotics within preceding 3 months.
A screening hemoglobin below 11.5 g/dL.
A screening TSH consistent with hypothyroidism.
Significant renal disease (eGFR < 60 ml/min) or acute nephritis
Clinically active hepatitis as evidenced by clinical jaundice or Grade 2 or higher liver function test abnormalities.
Hepatic cirrhosis or decompensated chronic liver disease.
Concurrent treatment with immunomodulatory drugs, such an interferon-alpha, or exposure to any immunomodulatory drug in past 16 weeks (outside of standard immunosuppression).
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 15
Group description: Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.

Injection Surgical anaesthesia

Adult: Epidural block: 50-100 mg (10-20 ml) of a 0.5% solution or 75-150 mg (10-20 ml) of a 0.75% solution. Caesarean section: 75-150 mg (15-30 ml) of a 0.5% solution. Spinal block: 15 mg (3 ml) of a 0.5% solution. Max: 150 mg/dose; 400 mg/day. Injection Peripheral nerve block

Read more: http://www.ndrugs.com/?s=levobupivacaine#ixzz3Xvp0iS5T

Levobupivacaine: this used in intratechal area and for spinal anesthesia in ceserean section
Eligibility criteria:
Inclusion Criteria:

pregnant women with a single live fetus aged 18-45 years old and classified as ASA I, undergoing elective cesarean section, were included the study in november 2006 to march 2007

Exclusion Criteria:

Multiple pregnancies,
preterm labor,
eclampsia,
preeclampsia,
concomitant diabetes mellitus,
allergy to local anesthetics, fentanyl or sufentanil,
contraindication for regional anesthesia were the exclusion criteria.
Intervention: Remifentanil
Trial phase: Not Applicable
ATC code: N01AH06
SMILES: CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).

Remifentanil: To determine if addition of remifentanil as an adjuvant with propofol will attenuate hemodynamic response to head pinning for the next ten minutes during and after pinning.
Eligibility criteria:
Inclusion Criteria:

Adult non-pregnant patients
undergoing general anesthesia for a craniotomy
requiring a Mayfield head fixation device.

Exclusion Criteria:

Patients under 18 years of age,
non-English speaking,
pregnancy,
opioid tolerance,
illegal drug use or alcohol abuse.
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).

Placebo
Eligibility criteria:
Inclusion Criteria:

Adult non-pregnant patients
undergoing general anesthesia for a craniotomy
requiring a Mayfield head fixation device.

Exclusion Criteria:

Patients under 18 years of age,
non-English speaking,
pregnancy,
opioid tolerance,
illegal drug use or alcohol abuse.
Intervention: Ketamine
Trial phase: Not Applicable
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 7
Group description: Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).

ketamine
Eligibility criteria:
Inclusion Criteria:

Eligible Long bone fractures. This will include:
Humerus
Tibia
Fibula
Femur
Radius
Ulna

Exclusion Criteria:

Injuries older than 24 hours
Avulsion fractures
History of substance abuse
History of chronic opioid dependence
Pregnancy
Demonstrates signs of intoxication
Allergic to ketamine or opioids
Patients unable to consent
Hemodynamically unstable (SBP >180mmHg or <100mgHg, HR >130bpm, Respiratory rate <10, oxygen saturations <90%
Intervention: Morphine
Trial phase: Not Applicable
ATC code: A07DA52 | N02AA01 | N02AA51 | N02AG01
SMILES: [H][C@@]12C=C[C@H](O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).

morphine
Eligibility criteria:
Inclusion Criteria:

Eligible Long bone fractures. This will include:
Humerus
Tibia
Fibula
Femur
Radius
Ulna

Exclusion Criteria:

Injuries older than 24 hours
Avulsion fractures
History of substance abuse
History of chronic opioid dependence
Pregnancy
Demonstrates signs of intoxication
Allergic to ketamine or opioids
Patients unable to consent
Hemodynamically unstable (SBP >180mmHg or <100mgHg, HR >130bpm, Respiratory rate <10, oxygen saturations <90%
Intervention: Olumacostat glasaretil
Trial phase: Phase 2
SMILES: CCCCCCCCCCCCCCOc1ccc(C(=O)OCC(=O)N(C)CC(=O)OCC)o1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 106
Group description: Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Signed informed consent.
Male or non-pregnant, non-lactating females.
Age ≥ 18 years.
Clinical diagnosis of facial acne vulgaris defined as:
At least 20 inflammatory lesions
At least 20 non-inflammatory lesions
Investigator Global Assessment of 3 or greater.

Exclusion Criteria:

Active cystic acne or acne conglobata, acne fulminans, and secondary acne.
Two or more active nodulocystic lesions.
Screening clinical chemistry or hematology laboratory value that is considered clinically significant, in the opinion of the Investigator.
Abnormal findings on screening ECG, deemed clinically significant, by the Investigator.
Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 30 days or 5 half-lives (whichever is longer) of the Baseline visit.
Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections, in the opinion of the investigator.
Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to Baseline.
Treatment with systemic corticosteroids (use of intranasal and inhaled corticosteroids allowed for seasonal allergies and asthma) within 4 weeks prior to Baseline.
Treatment with systemic antibiotics or systemic anti-acne drugs or systemic anti-inflammatory drugs within 4 weeks prior to Baseline.
Prescription topical retinoid use on the face within 4 weeks of Baseline (e.g., tretinoin, tazarotene, adapalene).
Treatment with a new hormonal therapy or dose change to existing hormonal therapy within 12 weeks prior to Baseline. Dose and frequency of use of any hormonal therapy started more than 12 weeks prior to Baseline must remain unchanged throughout the study. Hormonal therapies include, but are not limited to, estrogenic and progestational agents such as birth control pills.
Prior use of androgen receptor blockers (such as spironolactone or flutamide).
Oral retinoid use (e.g., isotretinoin) within 12 months prior to Baseline or vitamin A supplements greater than 10,000 units/day within 6 months of Baseline.
Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8 weeks or during the study.
Intervention: Olumacostat glasaretil
Trial phase: Phase 2
SMILES: CCCCCCCCCCCCCCOc1ccc(C(=O)OCC(=O)N(C)CC(=O)OCC)o1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 109
Group description: Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Signed informed consent.
Male or non-pregnant, non-lactating females.
Age ≥ 18 years.
Clinical diagnosis of facial acne vulgaris defined as:
At least 20 inflammatory lesions
At least 20 non-inflammatory lesions
Investigator Global Assessment of 3 or greater.

Exclusion Criteria:

Active cystic acne or acne conglobata, acne fulminans, and secondary acne.
Two or more active nodulocystic lesions.
Screening clinical chemistry or hematology laboratory value that is considered clinically significant, in the opinion of the Investigator.
Abnormal findings on screening ECG, deemed clinically significant, by the Investigator.
Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 30 days or 5 half-lives (whichever is longer) of the Baseline visit.
Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections, in the opinion of the investigator.
Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to Baseline.
Treatment with systemic corticosteroids (use of intranasal and inhaled corticosteroids allowed for seasonal allergies and asthma) within 4 weeks prior to Baseline.
Treatment with systemic antibiotics or systemic anti-acne drugs or systemic anti-inflammatory drugs within 4 weeks prior to Baseline.
Prescription topical retinoid use on the face within 4 weeks of Baseline (e.g., tretinoin, tazarotene, adapalene).
Treatment with a new hormonal therapy or dose change to existing hormonal therapy within 12 weeks prior to Baseline. Dose and frequency of use of any hormonal therapy started more than 12 weeks prior to Baseline must remain unchanged throughout the study. Hormonal therapies include, but are not limited to, estrogenic and progestational agents such as birth control pills.
Prior use of androgen receptor blockers (such as spironolactone or flutamide).
Oral retinoid use (e.g., isotretinoin) within 12 months prior to Baseline or vitamin A supplements greater than 10,000 units/day within 6 months of Baseline.
Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8 weeks or during the study.
Intervention: Olumacostat glasaretil
Trial phase: Phase 2
SMILES: CCCCCCCCCCCCCCOc1ccc(C(=O)OCC(=O)N(C)CC(=O)OCC)o1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 101
Group description: Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Signed informed consent.
Male or non-pregnant, non-lactating females.
Age ≥ 18 years.
Clinical diagnosis of facial acne vulgaris defined as:
At least 20 inflammatory lesions
At least 20 non-inflammatory lesions
Investigator Global Assessment of 3 or greater.

Exclusion Criteria:

Active cystic acne or acne conglobata, acne fulminans, and secondary acne.
Two or more active nodulocystic lesions.
Screening clinical chemistry or hematology laboratory value that is considered clinically significant, in the opinion of the Investigator.
Abnormal findings on screening ECG, deemed clinically significant, by the Investigator.
Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 30 days or 5 half-lives (whichever is longer) of the Baseline visit.
Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections, in the opinion of the investigator.
Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to Baseline.
Treatment with systemic corticosteroids (use of intranasal and inhaled corticosteroids allowed for seasonal allergies and asthma) within 4 weeks prior to Baseline.
Treatment with systemic antibiotics or systemic anti-acne drugs or systemic anti-inflammatory drugs within 4 weeks prior to Baseline.
Prescription topical retinoid use on the face within 4 weeks of Baseline (e.g., tretinoin, tazarotene, adapalene).
Treatment with a new hormonal therapy or dose change to existing hormonal therapy within 12 weeks prior to Baseline. Dose and frequency of use of any hormonal therapy started more than 12 weeks prior to Baseline must remain unchanged throughout the study. Hormonal therapies include, but are not limited to, estrogenic and progestational agents such as birth control pills.
Prior use of androgen receptor blockers (such as spironolactone or flutamide).
Oral retinoid use (e.g., isotretinoin) within 12 months prior to Baseline or vitamin A supplements greater than 10,000 units/day within 6 months of Baseline.
Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8 weeks or during the study.
Intervention: Verdinexor
Trial phase: Phase 1
SMILES: O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1ccccn1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Participants received verdinexor 10 mg tablet orally once daily on Days 1 and 3.
Eligibility criteria:
Inclusion Criteria:

Participants must be in good health as determined by the investigator, based on the medical history, ECG, physical examination, and safety laboratory tests at screening.
Participants must be identified as a non-smoker at the screening visit (a non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to the screening visit and who has a ≤ 15 pack year history of lifetime cigarette use). A urine cotinine test will be performed at screening and at the time of clinic check-in prior to study drug treatment.

Exclusion Criteria:

The participant has any surgical or medical condition that potentially may alter the absorption, metabolism, or excretion of the study drug such as gastrectomy, Crohn's disease, or liver disease.
The participant has a history of clinically significant allergies. Hay fever is allowed unless it is active or has required treatment within the previous 2 months.
Presence of a chronic condition(s) with clinical or historical evidence of recent exacerbation, or other information to suggest non-control of such condition(s).
History of alcohol abuse or drug addiction within 12 months of the screening visit.
Any participant with active cataracts or medical history of cataracts.
Intervention: Verdinexor
Trial phase: Phase 1
SMILES: O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1ccccn1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Participants received verdinexor 20 mg tablet (2 tablets of 10 mg each) orally once daily on Days 1 and 3.
Eligibility criteria:
Inclusion Criteria:

Participants must be in good health as determined by the investigator, based on the medical history, ECG, physical examination, and safety laboratory tests at screening.
Participants must be identified as a non-smoker at the screening visit (a non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to the screening visit and who has a ≤ 15 pack year history of lifetime cigarette use). A urine cotinine test will be performed at screening and at the time of clinic check-in prior to study drug treatment.

Exclusion Criteria:

The participant has any surgical or medical condition that potentially may alter the absorption, metabolism, or excretion of the study drug such as gastrectomy, Crohn's disease, or liver disease.
The participant has a history of clinically significant allergies. Hay fever is allowed unless it is active or has required treatment within the previous 2 months.
Presence of a chronic condition(s) with clinical or historical evidence of recent exacerbation, or other information to suggest non-control of such condition(s).
History of alcohol abuse or drug addiction within 12 months of the screening visit.
Any participant with active cataracts or medical history of cataracts.
Intervention: Verdinexor
Trial phase: Phase 1
SMILES: O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1ccccn1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Participants received verdinexor 40 mg tablet (4 tablets of 10 mg each) orally once daily on Days 1 and 3.
Eligibility criteria:
Inclusion Criteria:

Participants must be in good health as determined by the investigator, based on the medical history, ECG, physical examination, and safety laboratory tests at screening.
Participants must be identified as a non-smoker at the screening visit (a non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to the screening visit and who has a ≤ 15 pack year history of lifetime cigarette use). A urine cotinine test will be performed at screening and at the time of clinic check-in prior to study drug treatment.

Exclusion Criteria:

The participant has any surgical or medical condition that potentially may alter the absorption, metabolism, or excretion of the study drug such as gastrectomy, Crohn's disease, or liver disease.
The participant has a history of clinically significant allergies. Hay fever is allowed unless it is active or has required treatment within the previous 2 months.
Presence of a chronic condition(s) with clinical or historical evidence of recent exacerbation, or other information to suggest non-control of such condition(s).
History of alcohol abuse or drug addiction within 12 months of the screening visit.
Any participant with active cataracts or medical history of cataracts.